



Application No. 09/849,967

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."  
*See the attached Error Report*
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212 *571-272-2501*

For PatentIn software help, call (703) 308-6856

*Anne Marie Corrigan*

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**



## **STIC Biotechnology Systems Branch**

### **RAW SEQUENCE LISTING** **ERROR REPORT**

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/849,967B  
Source: IFW/b  
Date Processed by STIC: 10/19/06

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER VERSION 4.4.0 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebs/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):  
U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/10/06



IFW16

**RAW SEQUENCE LISTING**

DATE: 10/19/2006

PATENT APPLICATION: US/09/849,967B

TIME: 10:18:14

Input Set : F:\NYMC-2.ST251.txt

Output Set: N:\CRF4\10192006\I849967B.raw

3 <110> APPLICANT: New York Medical College  
5 <120> TITLE OF INVENTION: Splice Choice Antagonists as Therapeutic Agents  
7 <130> FILE REFERENCE: 51230-00601  
9 <140> CURRENT APPLICATION NUMBER: 09/849,967B  
10 <141> CURRENT FILING DATE: 2001-05-08  
E--> 12 <160> NUMBER OF SEQ ID NOS: 4 *see p. 2*  
14 <170> SOFTWARE: PatentIn version 3.3

ERRORED SEQUENCES

**Does Not Comply  
Corrected Diskette Needed**

09/849,967B 2

<210> 7 *last sequence in submitted file*  
<211> 8  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (1)..(1)  
<223> Xaa represents a Lysine or an Arginine

<220>  
<221> SITE  
<222> (3)..(3)  
<223> Xaa represents a phenylalanine or tyrosine

<220>  
<221> SITE  
<222> (4)..(4)  
<223> Xaa represents a glycine or alanine

<220>  
<221> misc\_feature  
<222> (7)..(7)  
<223> Xaa can be any naturally occurring amino acid

<220>  
<221> SITE  
<222> (8)..(8)  
<223> Xaa represents a phenylalanine or tyrosine

<400> 7

Xaa Gly Xaa Xaa Pro Val Xaa Xaa  
1 5

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/849,967B

DATE: 10/19/2006

TIME: 10:18:15

Input Set : F:\NYMC-2.ST251.txt

Output Set: N:\CRF4\10192006\I849967B.raw

L:410 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7 after pos.:0  
L:12 M:203 E: No. of Seq. differs, <160> Number Of Sequences:Input (4) Counted (7)